Literature DB >> 23103332

Immune aspects of the pathogenesis of inflammatory bowel disease.

Tadakazu Hisamatsu1, Takanori Kanai, Yohei Mikami, Kazuaki Yoneno, Katsuyoshi Matsuoka, Toshifumi Hibi.   

Abstract

Although the precise etiologies of inflammatory bowel disease (IBD) (ulcerative colitis and Crohn's disease) remain obscure, several reports have indicated that dysfunction of the mucosal immune system plays an important role in its pathogenesis. Recent progress with genome-wide association studies has identified many IBD susceptibility genes. In individuals with genetic risk, abnormal interactions between the host immune system and gut flora, and dysregulation of cellular responses such as autophagy and ER stress, induce an abnormal host immune response in the gut resulting in intestinal inflammation. Research progress animal models in IBD, and in human IBD, has identified several key molecules in IBD pathogenesis such as TNFα and adhesion molecules, and molecular targeting therapies based on these molecules have been developed. Here, we review immunological aspects in IBD pathogenesis and the development of immunoregulatory therapy.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23103332     DOI: 10.1016/j.pharmthera.2012.10.008

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  37 in total

1.  Cyclooxygenase-2 silencing for the treatment of colitis: a combined in vivo strategy based on RNA interference and engineered Escherichia coli.

Authors:  Enzo Spisni; Maria C Valerii; Luigia De Fazio; Elena Cavazza; Francesca Borsetti; Annamaria Sgromo; Marco Candela; Manuela Centanni; Fernando Rizello; Antonio Strillacci
Journal:  Mol Ther       Date:  2014-11-13       Impact factor: 11.454

2.  Interleukin-25 enhances the capacity of mesenchymal stem cells to induce intestinal epithelial cell regeneration.

Authors:  Jingling Su; Chenxi Xie; Yanyun Fan; Weizi Cheng; Yiqun Hu; Qingwen Huang; Huaxiu Shi; Lin Wang; Jianlin Ren
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

Review 3.  Control of autoimmune inflammation by celastrol, a natural triterpenoid.

Authors:  Shivaprasad H Venkatesha; Steven Dudics; Brian Astry; Kamal D Moudgil
Journal:  Pathog Dis       Date:  2016-07-11       Impact factor: 3.166

Review 4.  Biological therapy for ulcerative colitis: an update.

Authors:  Geom Seog Seo; Soo-Cheon Chae
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

Review 5.  Enteric microbiota leads to new therapeutic strategies for ulcerative colitis.

Authors:  Wei-Xu Chen; Li-Hua Ren; Rui-Hua Shi
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

6.  Basiliximab treatment for autoimmune bowel disease in a pediatric heart transplant patient.

Authors:  K Puri; S Kocoshis; K Risma; L Perez; C Hart; C Chin; T D Ryan; J L Jefferies; K R Schumacher; C Castleberry
Journal:  Pediatr Transplant       Date:  2015-09-16

Review 7.  Influence of host immunoregulatory genes, ER stress and gut microbiota on the shared pathogenesis of inflammatory bowel disease and Type 1 diabetes.

Authors:  Altin Gjymishka; Roxana M Coman; Todd M Brusko; Sarah C Glover
Journal:  Immunotherapy       Date:  2013-12       Impact factor: 4.196

8.  Effects of the Sijunzi decoction on the immunological function in rats with dextran sulfate-induced ulcerative colitis.

Authors:  Wangui Yu; Bing Lu; Hengwen Zhang; Yanxiang Zhang; Jin Yan
Journal:  Biomed Rep       Date:  2016-05-16

Review 9.  Implication of miRNAs for inflammatory bowel disease treatment: Systematic review.

Authors:  Wei-Xu Chen; Li-Hua Ren; Rui-Hua Shi
Journal:  World J Gastrointest Pathophysiol       Date:  2014-05-15

10.  Interleukin-25 primed mesenchymal stem cells achieve better therapeutic effects on dextran sulfate sodium-induced colitis via inhibiting Th17 immune response and inducing T regulatory cell phenotype.

Authors:  Weizi Cheng; Jingling Su; Yiqun Hu; Qingwen Huang; Huaxiu Shi; Lin Wang; Jianlin Ren
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.